ReviewSeminars in cell & developmental biology2016
Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders.
Review in Seminars in cell & developmental biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 71 citations in OpenAlex.
- Prenatal stress selectively enhances locomotor hyperactivity in male mice with embryonic loss ofFrontiers in psychiatry · 2026Article
- Association between baseline circulating FGF21 levels and depressive symptoms at follow up in older adults: evidence from the FRASNET cohort.Frontiers in psychiatry · 2026Article
- Across Barriers: Blood-Brain and Gut Barrier Signaling in Psychiatric Disorders.Journal of neurochemistry · 2025Review
- Adverse drug reaction profiles of histone deacetylase inhibitors.Scientific reports · 2025Article
- Article
- The relationship between salivary Fibroblast Growth Factor-2 and cortisol reactivity and psychological outcomes prior to and during the COVID-19 pandemic.Journal of affective disorders reports · 2023Article
- Roles of Fibroblast Growth Factors in the Axon Guidance.International journal of molecular sciences · 2023Review
- Maternal FGF2 levels associated with child anxiety and depression symptoms through child FGF2 levels.Journal of affective disorders · 2023Article
- Identification and Validation of FGF-Related Prognostic Signatures in Prostate Cancer.Disease markers · 2023Article
- Research progress of fibroblast growth factor in nervous system diseases.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022Article
- Article
- Chronic Trazodone and Citalopram Treatments Increase Trophic Factor and Circadian Rhythm Gene Expression in Rat Brain Regions Relevant for Antidepressant Efficacy.International journal of molecular sciences · 2022Article
- Article
- New developments in the biology of fibroblast growth factors.WIREs mechanisms of disease · 2022Review
- Characterization of cell-cell communication in autistic brains with single-cell transcriptomes.Journal of neurodevelopmental disorders · 2022Article
- Multivariate genomic and transcriptomic determinants of imaging-derived personalized therapeutic needs in Parkinson's disease.Scientific reports · 2022Article
- A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism.Patterns (New York, N.Y.) · 2022Article
- Review
- Re-emerging concepts of immune dysregulation in autism spectrum disorders.Frontiers in psychiatry · 2022Review
- Fibroblast Growth Factor Signalling in the Diseased Nervous System.Molecular neurobiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
The role of the fibroblast growth factor (FGF) system in brain-related disorders has received considerable attention in recent years. To understand the role of this system in neurological and psychiatric disorders, it is important to identify the specific members of the FGF family that are implicated, their location and the various mechanisms they can be modulated. Each disorder appears to impact specific molecular players in unique anatomical locations, and all of these could conceivably become targets for treatment. In the last several years, the issue of how to target this system directly has become an area of increasing interest. To date, the most promising therapeutics are small molecule inhibitors and antibodies that modulate FGF receptor (FGFR) function. Beyond attempting to modify the primary players affected by a given brain disorder, it may prove useful to target molecules, such as membrane-bound or extracellular proteins that interact with FGF ligands or FGFRs to modulate signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.